The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Benjamin Solomon, Benjamin Besse, Todd M. Bauer et al. · The Lancet Oncology · 2018 · 789 citations

Medicine, Oncology, Medical Oncology +10

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Alice T. Shaw, Enriqueta Felip, Todd M. Bauer et al. · The Lancet Oncology · 2017 · 649 citations · Full text

Medicine, Oncology, Pharmacology +14

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

Ted W. Johnson, Paul Richardson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 585 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury

Mercedes Robles‐Díaz, M. Isabel Lucena, Neil Kaplowitz et al. · Gastroenterology · 2014 · 325 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients

Rovina Ruslami, Hanneke M. J. Nijland, Bachti Alisjahbana et al. · Antimicrobial Agents and Chemotherapy · 2007 · 179 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8